A Double-Blind, Placebo Controlled Clinical Trial Evaluating the Efficacy and Safety of a New Skin Whitening Combination in Patients with Chloasma


Melasma (or chloasma) is a hyperpigmentation disorder predominantly affecting sun-exposed skin in women, and is often refractory to treatment. The objective was to evaluate the efficacy and safety of a new whitening formula for the treatment of chloasma. This single centre, double-blind, placebo controlled, bilateral (split-face) comparison, was conducted on 44 Chinese subjects with chloasma during the winter season. The test formula was applied twice a day, for 12 weeks on left side of the face and a placebo formula on the right side of the face. Assessments included the use of the hemi-MASI (split-face Melasma Area Severity Index), both ultraviolet and standard photography, together with clinical evaluations of efficacy and safety at T0, T6 and T12 weeks. A significant difference between the 2-hemi-MASI was noticed after 6 and 12 weeks of treatment. This result was confirmed by the clinical evaluation of the dermatologists who recorded a significant improvement in the half-face treated with the new whitening formula compared with that treated with placebo (p = 0.003). The tolerance of the new formula was recorded as excellent by 82% of subjects and found to be cosmetically appealing. In this study, the new whitening formula containing ferulic acid, Ginkgo Biloba, lipohydroxyacid (LHA), niacinamide and thermal spring water was safe and significantly improved chloasma after a 3-month-treatment period compared with placebo.

Share and Cite:

Wang, X. , Li, Z. , Zhang, D. , Li, L. and Sophie, S. (2014) A Double-Blind, Placebo Controlled Clinical Trial Evaluating the Efficacy and Safety of a New Skin Whitening Combination in Patients with Chloasma. Journal of Cosmetics, Dermatological Sciences and Applications, 4, 92-98. doi: 10.4236/jcdsa.2014.42014.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Jimbow, M. and Jimbow, K. (1989) Pigmentary Disorders in Oriental Skin. Clinics in Dermatology, 7, 11-27. http://dx.doi.org/10.1016/0738-081X(89)90053-9
[2] Chung, J.H. (2003) Photoaging in Asians. Photodermatology, Photoimmunology & Photomedicine, 19, 109-121. http://dx.doi.org/10.1034/j.1600-0781.2003.00027.x
[3] Ho, S.G. and Chan, H.H. (2009) The Asian Dermatologic Patient: Review of Common Pigmentary Disorders and Cutaneous Diseases. American Journal of Clinical Dermatology, 10, 153-168.
[4] Wand, R., Xu, Z., Tang, Y., Zhang, J., Wang, Z., Cao, L., Shen, Z., Zhou, C., Ding, X., Zheng, D., Gui, B. and Zhu, X. (2010) Prevalence of Melasma in Chinese Han and Chinese Yi: A Survey in Liangshan Distric. The Chinese Journal of Dermatovenereology, 6, 546-548.
[5] Balkrishnan, R., Kelly, A.P., McMichael, A. and Torok, H. (2004) Improved Quality of Life with Effective Treatment of Facial Melasma: The Pigment Trial. Journal of Drugs in Dermatology, 3, 377-381.
[6] Perez, M.L. (2005) The Stepwise Approach to the Treatment of Melasma. Cutis, 75, 217-222.
[7] Victor, F.C., Gelber, J. and Rao, B. (2004) Melasma: A Review. Journal of Cutaneous Medicine and Surgery, 8, 97-102. http://dx.doi.org/10.1007/s10227-004-0158-9
[8] Sharquie, K.E., Al-Tirkreety, M.M. and Al-Mahhadani, S.A. (2005) Lactic Acid as a New Therapeutic Peeling Agent in Melasma. Dermatologic Surgery, 31, 149-154. http://dx.doi.org/10.1111/j.1524-4725.2005.31035
[9] Espinal-Perez, L.E., Moncada, B. and Castanedo-Cazares, J.P. (2004) A Double Blind Randomized Trial of 5% Ascorbic Acid vs. 4% Hydroquinone in Melasma. International Journal of Dermatology, 43, 604-607. http://dx.doi.org/10.1111/j.1365-4632.2004.02134.x
[10] Torok, H.M., Jones, T., Rich, P., Smith, S. and Tschen, E. (2005) Hydroquinone 4%, Tretinoin 0.05%, Flucinoloneacetonide 0.01%: A Safe and Efficious 12-Month Treatment for Melasma. Cutis, 75, 57-62.
[11] Lee, H.S. (2002) Tyrosinase Inhibitors of Pulsatillacernua Root-Derived Materials. Journal of Agricultural and Food Chemistry, 50, 1400-1403. http://dx.doi.org/10.1021/jf011230f
[12] Fong, P. and Tong, H.H. (2012) Insilico Prediction of the Cosmetic Whitening Effects of Naturally Occurring Lead Compounds. Natural Product Communications, 7, 1287-1294.
[13] Tsuno, T. and Kadota, M. (2002) Application to the Cosmetics as an Ultraviolet Ray Absorbent of Ferulic Acid. Fragrance Journal, 30, 137.
[14] Saint-Leger, D., Leveque, J.L. and Verschoore, M. (2007) The Use of Hydroxy Acids on the Skin: Characteristics of C8-Lipohydroxy Acid. Journal of Cosmetic Dermatology, 6, 59-65.
[15] Hakozaki, T., Minwalla, L., Zhuang, J., et al. (2002) The Effect of Niacinamide on Reducing Cutaneous Pigmentation and Suppression of Melanosome Transfer. British Journal of Dermatology, 147, 20-31. http://dx.doi.org/10.1046/j.1365-2133.2002.04834.x
[16] Seité, S. (2013) Thermal Waters as Cosmeceuticals: La Roche Posay Thermal Spring Water Example. Clinical, Cosmetic and Investigational Dermatology, 6, 1-6.
[17] Kimbrough-Green, C.K., et al. (1994) Topical Retinoic Acid (Tretinoin) for Melasma in Black Patients. Archives of Dermatology, 130, 727-733. http://dx.doi.org/10.1001/archderm.1994.01690060057005
[18] Xiang, D.K. (2003) Natural Plant Actives-Ferulic Acid. China Cosmetics (Industry), 20, 76.
[19] Staniforth, V., Huang, W.C. and Aravindaram, K. (2011) Ferulic Acid, a Phenolic Phytochemical, Inhibits UVB-Induced Matrix Metalloproteinases in Mouse Skin via Posttranslational Mechanisms. The Journal of Nutritional Biochemistry, 23, 443-451.
[20] Oresajo, C., Stephens, T., Hino, P.D., et al. (2008) Protective Effects of a Topical Antioxidant Mixture Containing Vitamin C, Ferulic Acid, and Phloretin against Ultraviolet-Induced Photodamage in Human Skin. Journal of Cosmetic Dermatology, 7, 290-297. http://dx.doi.org/10.1111/j.1473-2165.2008. 00408.x
[21] Murray, J.C., Burch, J.A., Streilein, R.D., Iannacchione, M.A., Hall, R.P. and Pinnell, S.R. (2008) A Topical Antioxidant Solution Containing Vitamins C and E Stabilized by Ferulic Acid Provides Protection for Human Skin against Damage Caused by Ultraviolet Irradiation. Journal of the American Academy of Dermatology, 59, 418-425. http://dx.doi.org/10.1016/j.jaad.2008.05.004

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.